ProMIS Neurosciences Inc 2026年季度报告

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller As of May 12, 2026, the registrant had 8,967,693 Common Shares outstanding. Table of Contents DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains statements that we believe are, or may be considered to be, “forward-looking statements.” Forward-looking statements are neither historical facts nor assurances of future performance.Instead, they are based on current beliefs, expectations or assumptions regarding the future of the business, futureplans and strategies, operational results and other future conditions of the Company. All statements other thanstatements of historical fact included in this Quarterly Report on Form 10-Q regarding the prospects of our industry orour prospects, plans, financial position or business strategy may constitute forward-looking statements. In addition,forward-looking statements generally can be identified by the use of forward-looking words such as “plans,” “expects”or “does not expect,” “is expected,” “look forward to,” “budget,” “scheduled,” “estimates,” “forecasts,” “willcontinue,” “intends,” “the intent of,” “have the potential,” “anticipates,” “does not anticipate,” “believes,” “should,”“should not,” or variations of such words and phrases that indicate that certain actions, events or results “may,” Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to: ●the anticipated amount, timing and accounting of contingent, milestone, royalty and other payments underlicensing or collaboration agreements;●tax positions and contingencies; research and development costs; compensation and other selling, general andadministrative expense;●foreign currency exchange risk;●estimated fair value of assets and liabilities; and impairment assessments;●the potential impact of increased competition in the markets in which we compete;●patent terms, patent term extensions, patent office actions and expected availability and period of regulatoryexclusivity;●our plans and investments in our portfolio as well as implementation of our corporate strategy;●the risk that we will maintain enough liquidity to execute our business plan;●our expected use of proceeds from sales of our common shares or common share equivalents in offerings or“at-the-market” offerings and the period over which such proceeds, together with existing cash, will besufficient to meet our operating needs; ●the potential impact of healthcare reform in the United States and measures being taken worldwide designedto reduce healthcare costs and limit the overall level of government expenditures, including the impact ofpricing actions and reduced reimbursement for our product candidates, if approved;●the impact of the continued uncertainty of the credit and economic conditions in certain countries and ourcollection of accounts receivable in such countries;●the risk that we become characterized as a passive foreign investment company; By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific,and risks exist that predictions, forecasts, projections and other forward-looking statements will not be achieved. Wecaution readers not to place undue reliance on these statements as a number of important factors could cause the actualresults to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentionsexpressed in such forward-looking statements. Risks, uncertainties and other factors which may cause the actualresults, performance or achievements of ProMIS Neurosciences Inc. (the “Company”), as applicable, to be materiallydifferent from any future results, performance or achievements expressed or implied by such forward-looking Readers are cautioned not to place undue reliance on any forward-looking statements contained in this QuarterlyReport on Form 10-Q, which reflect management’s opinions only as of the date hereof. Except as required by law, weundertake no obligation to revise or publicly release the results of any revision to any forward-looking statements. Youare advised, however, to consult any additional disclosures we make in our reports to the SEC. All subsequent written PART I—FINANCIAL INFORMATION PROMIS NEUROSCIENCESINC. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. PROMIS NEUROSCIENCESINC. Notesto Unaudited Condensed Consolidated Financial Statements (expressed in US dollars, except share and per share amounts)(Unaudited) 1.DESCRIPTION OF BUSINESS Business Description ProMIS NeurosciencesInc. (the “Company” or “ProMIS”) is applying its patented technology platform tobuilda portfolio of antibody therapies